Compare UiPath Inc (PATH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs TG Therapeutics Inc — how do they compare? UiPath Inc trades at $13.56 (market cap $6.91B), while TG Therapeutics Inc trades at $54.94 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and TG Therapeutics Inc for 15 Days on average.
| PATH | TGTX | |
|---|---|---|
Market Cap | $6.91B | $8.16B |
Volume | 34,321,250 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $19.29 | $59.06 |
52-Week Low | $9.38 | $26.94 |
Typical Hold Time | 139 Days | 15 Days |
Enterprise Value | $5.70B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.07, down 0.23% with bearish technical signals despite strong fundamentals. The company shows improving financials with revenue growth from $1.43B in 2025 to projected $1.7B in 2026, transitioning to profitability with a 21.03% net margin. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though technical indicators show resistance at $13 with RSI suggesting mixed momentum.
PATH offers compelling value with a P/E of 19.78 and analyst consensus target of $15.13 (16% upside), but faces execution risks and competitive pressure. The stock's bearish technical setup contrasts with fundamental improvement, creating potential for volatility. Investors should weigh strong profitability metrics against recent price weakness and mixed analyst sentiment.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% on the day, with a bearish technical signal from moving averages despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results have missed expectations. Analyst sentiment remains largely positive, with an 84.62% buy rating and a consensus price target of $80.50, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook for TGTX is mixed, with robust revenue guidance and product momentum offset by earnings misses and negative cash flow. Key opportunities include BRIUMVI's expanding market share and potential buyout speculation, but risks involve ongoing legal scrutiny, competitive pressures, and the need to translate top-line growth into consistent bottom-line performance amid significant cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
